Publisher: EDRA SpA   (Total: 1 journals)   [Sort by number of followers]

Showing 1 - 1 of 1 Journals sorted alphabetically
European Annals of Allergy and Clinical Immunology     Open Access   (Followers: 4, SJR: 0.441, CiteScore: 1)
Similar Journals
Journal Cover
European Annals of Allergy and Clinical Immunology
Journal Prestige (SJR): 0.441
Citation Impact (citeScore): 1
Number of Followers: 4  

  This is an Open Access Journal Open Access journal
ISSN (Print) 1764-1489
Published by EDRA SpA Homepage  [1 journal]
  • Der p 23 sensitisation in patients with house dust mite respiratory
           allergy

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. Der p 23 might be a prevalent allergen in regions with high rates of HDM exposure. Even though sIgE levels against this allergen are usually low, its presence could increase the risk of asthma.PMID:35899400
      DOI :10.23822/EurAnnACI.1764-1489.264 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Thu, 11 Aug 2022 16:21:40 +010
       
  • Kounis Syndrome: an underestimated emergency

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. The present study highlights the importance of suspicion of KS that appears not so uncommon in patients with anaphylaxis. KS seems to be a rare disease because unrecognized in diagnosis of anaphylaxis.PMID:35850501
      DOI :10.23822/EurAnnACI.1764-1489.260 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 31 Jul 2022 04:32:37 +010
       
  • Bronchospasm and iodinated contrast media (ICM): an accurate evaluation is
           mandatory

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Jul 18. doi: 10.23822/EurAnnACI.1764-1489.262. Online ahead of print.NO ABSTRACTPMID:35850502
      DOI :10.23822/EurAnnACI.1764-1489.262 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 31 Jul 2022 04:32:37 +010
       
  • Can dose reduction be made in patients with allergic bronchopulmonary
           aspergillosis receiving high-dose omalizumab treatment'

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. Decreasing the total omalizumab dose does not cause clinical deterioration in ABPA after the disease is controlled.PMID:35850503
      DOI :10.23822/EurAnnACI.1764-1489.261 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 31 Jul 2022 04:32:37 +010
       
  • SARS-CoV-2 pandemics and RSV off-season outbreaks

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Jul 9. doi: 10.23822/EurAnnACI.1764-1489.263. Online ahead of print.NO ABSTRACTPMID:35852514
      DOI :10.23822/EurAnnACI.1764-1489.263 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 31 Jul 2022 04:32:37 +010
       
  • Kounis Syndrome: an underestimated emergency

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. The present study highlights the importance of suspicion of KS that appears not so uncommon in patients with anaphylaxis. KS seems to be a rare disease because unrecognized in diagnosis of anaphylaxis.PMID:35850501
      DOI :10.23822/EurAnnACI.1764-1489.260 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 31 Jul 2022 04:32:37 +010
       
  • Bronchospasm and iodinated contrast media (ICM): an accurate evaluation is
           mandatory

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Jul 18. doi: 10.23822/EurAnnACI.1764-1489.262. Online ahead of print.NO ABSTRACTPMID:35850502
      DOI :10.23822/EurAnnACI.1764-1489.262 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 31 Jul 2022 04:32:37 +010
       
  • Can dose reduction be made in patients with allergic bronchopulmonary
           aspergillosis receiving high-dose omalizumab treatment'

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. Decreasing the total omalizumab dose does not cause clinical deterioration in ABPA after the disease is controlled.PMID:35850503
      DOI :10.23822/EurAnnACI.1764-1489.261 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 31 Jul 2022 04:32:37 +010
       
  • SARS-CoV-2 pandemics and RSV off-season outbreaks

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Jul 9. doi: 10.23822/EurAnnACI.1764-1489.263. Online ahead of print.NO ABSTRACTPMID:35852514
      DOI :10.23822/EurAnnACI.1764-1489.263 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 31 Jul 2022 04:32:37 +010
       
  • Kounis Syndrome: an underestimated emergency

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. The present study highlights the importance of suspicion of KS that appears not so uncommon in patients with anaphylaxis. KS seems to be a rare disease because unrecognized in diagnosis of anaphylaxis.PMID:35850501
      DOI :10.23822/EurAnnACI.1764-1489.260 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 31 Jul 2022 04:32:37 +010
       
  • Bronchospasm and iodinated contrast media (ICM): an accurate evaluation is
           mandatory

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Jul 18. doi: 10.23822/EurAnnACI.1764-1489.262. Online ahead of print.NO ABSTRACTPMID:35850502
      DOI :10.23822/EurAnnACI.1764-1489.262 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 31 Jul 2022 04:32:37 +010
       
  • Can dose reduction be made in patients with allergic bronchopulmonary
           aspergillosis receiving high-dose omalizumab treatment'

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. Decreasing the total omalizumab dose does not cause clinical deterioration in ABPA after the disease is controlled.PMID:35850503
      DOI :10.23822/EurAnnACI.1764-1489.261 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 31 Jul 2022 04:32:37 +010
       
  • SARS-CoV-2 pandemics and RSV off-season outbreaks

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Jul 9. doi: 10.23822/EurAnnACI.1764-1489.263. Online ahead of print.NO ABSTRACTPMID:35852514
      DOI :10.23822/EurAnnACI.1764-1489.263 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 31 Jul 2022 04:32:37 +010
       
  • Kounis Syndrome: an underestimated emergency

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. The present study highlights the importance of suspicion of KS that appears not so uncommon in patients with anaphylaxis. KS seems to be a rare disease because unrecognized in diagnosis of anaphylaxis.PMID:35850501
      DOI :10.23822/EurAnnACI.1764-1489.260 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 31 Jul 2022 04:32:37 +010
       
  • Bronchospasm and iodinated contrast media (ICM): an accurate evaluation is
           mandatory

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Jul 18. doi: 10.23822/EurAnnACI.1764-1489.262. Online ahead of print.NO ABSTRACTPMID:35850502
      DOI :10.23822/EurAnnACI.1764-1489.262 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 31 Jul 2022 04:32:37 +010
       
  • Can dose reduction be made in patients with allergic bronchopulmonary
           aspergillosis receiving high-dose omalizumab treatment'

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. Decreasing the total omalizumab dose does not cause clinical deterioration in ABPA after the disease is controlled.PMID:35850503
      DOI :10.23822/EurAnnACI.1764-1489.261 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 31 Jul 2022 04:32:37 +010
       
  • SARS-CoV-2 pandemics and RSV off-season outbreaks

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Jul 9. doi: 10.23822/EurAnnACI.1764-1489.263. Online ahead of print.NO ABSTRACTPMID:35852514
      DOI :10.23822/EurAnnACI.1764-1489.263 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 31 Jul 2022 04:32:37 +010
       
  • Kounis Syndrome: an underestimated emergency

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. The present study highlights the importance of suspicion of KS that appears not so uncommon in patients with anaphylaxis. KS seems to be a rare disease because unrecognized in diagnosis of anaphylaxis.PMID:35850501
      DOI :10.23822/EurAnnACI.1764-1489.260 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 31 Jul 2022 04:32:37 +010
       
  • Bronchospasm and iodinated contrast media (ICM): an accurate evaluation is
           mandatory

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Jul 18. doi: 10.23822/EurAnnACI.1764-1489.262. Online ahead of print.NO ABSTRACTPMID:35850502
      DOI :10.23822/EurAnnACI.1764-1489.262 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 31 Jul 2022 04:32:37 +010
       
  • Can dose reduction be made in patients with allergic bronchopulmonary
           aspergillosis receiving high-dose omalizumab treatment'

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. Decreasing the total omalizumab dose does not cause clinical deterioration in ABPA after the disease is controlled.PMID:35850503
      DOI :10.23822/EurAnnACI.1764-1489.261 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 31 Jul 2022 04:32:37 +010
       
  • SARS-CoV-2 pandemics and RSV off-season outbreaks

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Jul 9. doi: 10.23822/EurAnnACI.1764-1489.263. Online ahead of print.NO ABSTRACTPMID:35852514
      DOI :10.23822/EurAnnACI.1764-1489.263 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 31 Jul 2022 04:32:37 +010
       
  • Kounis Syndrome: an underestimated emergency

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. The present study highlights the importance of suspicion of KS that appears not so uncommon in patients with anaphylaxis. KS seems to be a rare disease because unrecognized in diagnosis of anaphylaxis.PMID:35850501
      DOI :10.23822/EurAnnACI.1764-1489.260 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 24 Jul 2022 00:30:40 +010
       
  • Bronchospasm and iodinated contrast media (ICM): an accurate evaluation is
           mandatory

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Jul 18. doi: 10.23822/EurAnnACI.1764-1489.262. Online ahead of print.NO ABSTRACTPMID:35850502
      DOI :10.23822/EurAnnACI.1764-1489.262 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 24 Jul 2022 00:30:40 +010
       
  • Can dose reduction be made in patients with allergic bronchopulmonary
           aspergillosis receiving high-dose omalizumab treatment'

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. Decreasing the total omalizumab dose does not cause clinical deterioration in ABPA after the disease is controlled.PMID:35850503
      DOI :10.23822/EurAnnACI.1764-1489.261 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 24 Jul 2022 00:30:40 +010
       
  • SARS-CoV-2 pandemics and RSV off-season outbreaks

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Jul 9. doi: 10.23822/EurAnnACI.1764-1489.263. Online ahead of print.NO ABSTRACTPMID:35852514
      DOI :10.23822/EurAnnACI.1764-1489.263 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 24 Jul 2022 00:30:40 +010
       
  • Kounis Syndrome: an underestimated emergency

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. The present study highlights the importance of suspicion of KS that appears not so uncommon in patients with anaphylaxis. KS seems to be a rare disease because unrecognized in diagnosis of anaphylaxis.PMID:35850501
      DOI :10.23822/EurAnnACI.1764-1489.260 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 24 Jul 2022 00:30:40 +010
       
  • Bronchospasm and iodinated contrast media (ICM): an accurate evaluation is
           mandatory

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Jul 18. doi: 10.23822/EurAnnACI.1764-1489.262. Online ahead of print.NO ABSTRACTPMID:35850502
      DOI :10.23822/EurAnnACI.1764-1489.262 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 24 Jul 2022 00:30:40 +010
       
  • Can dose reduction be made in patients with allergic bronchopulmonary
           aspergillosis receiving high-dose omalizumab treatment'

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. Decreasing the total omalizumab dose does not cause clinical deterioration in ABPA after the disease is controlled.PMID:35850503
      DOI :10.23822/EurAnnACI.1764-1489.261 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 24 Jul 2022 00:30:40 +010
       
  • SARS-CoV-2 pandemics and RSV off-season outbreaks

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Jul 9. doi: 10.23822/EurAnnACI.1764-1489.263. Online ahead of print.NO ABSTRACTPMID:35852514
      DOI :10.23822/EurAnnACI.1764-1489.263 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 24 Jul 2022 00:30:40 +010
       
  • Kounis Syndrome: an underestimated emergency

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. The present study highlights the importance of suspicion of KS that appears not so uncommon in patients with anaphylaxis. KS seems to be a rare disease because unrecognized in diagnosis of anaphylaxis.PMID:35850501
      DOI :10.23822/EurAnnACI.1764-1489.260 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 24 Jul 2022 00:30:40 +010
       
  • Bronchospasm and iodinated contrast media (ICM): an accurate evaluation is
           mandatory

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Jul 18. doi: 10.23822/EurAnnACI.1764-1489.262. Online ahead of print.NO ABSTRACTPMID:35850502
      DOI :10.23822/EurAnnACI.1764-1489.262 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 24 Jul 2022 00:30:40 +010
       
  • Can dose reduction be made in patients with allergic bronchopulmonary
           aspergillosis receiving high-dose omalizumab treatment'

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. Decreasing the total omalizumab dose does not cause clinical deterioration in ABPA after the disease is controlled.PMID:35850503
      DOI :10.23822/EurAnnACI.1764-1489.261 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 24 Jul 2022 00:30:40 +010
       
  • SARS-CoV-2 pandemics and RSV off-season outbreaks

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Jul 9. doi: 10.23822/EurAnnACI.1764-1489.263. Online ahead of print.NO ABSTRACTPMID:35852514
      DOI :10.23822/EurAnnACI.1764-1489.263 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 24 Jul 2022 00:30:40 +010
       
  • Concomitant evaluation of d-dimer and C-reactive protein in chronic
           spontaneous urticaria may show divergent values

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Jul 4. doi: 10.23822/EurAnnACI.1764-1489.259. Online ahead of print.NO ABSTRACTPMID:35791699
      DOI :10.23822/EurAnnACI.1764-1489.259 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 24 Jul 2022 00:30:40 +010
       
  • Contact sensitization in pediatric patients with atopic dermatitis: a
           purpose for a new patch testing serie for the Portuguese population

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Jun 9. doi: 10.23822/EurAnnACI.1764-1489.258. Online ahead of print.ABSTRACTAtopic dermatitis is a common illness in pediatric age. Children with atopic dermatitis are prone to develop cutaneous sensitization due to skin barrier dysfunction and immune dysregulation. Recent studies have shown a higher prevalence of certain allergens, which identification may be clinically relevant and have implications for atopic dermatitis management. Considering the most prevalent and relevant allergens based on a retrospective analysis of 145 pediatric patients, 44.1% (n = 63) with atopic dermatitis, and comparing the positive results, we propose the application of an adapted baseline series with the most relevant 20 allergens for the Portuguese pediatric population wit...
      PubDate: Thu, 07 Jul 2022 00:48:42 +010
      DOI: 10.23822/eurannaci.1764-1489.258. online ahead of print.abstractatopic dermatitis is a common illnes
       
  • The impact of the COVID-19 pandemic in Hymenoptera Venom Immunotherapy: a
           single center experience

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Jun 9. doi: 10.23822/EurAnnACI.1764-1489.257. Online ahead of print.NO ABSTRACTPMID:35678606
      DOI :10.23822/EurAnnACI.1764-1489.257 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sat, 11 Jun 2022 22:31:04 +010
       
  • Overview of asthma patients followed up in a Tertiary Clinic

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. Our study showed that different phenotypes were more closely related to some endotypes. This may allow the clinicians to identify patients and predict appropriate treatment modalities and response for individualized care.PMID:35670696
      DOI :10.23822/EurAnnACI.1764-1489.256 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sat, 11 Jun 2022 22:31:04 +010
       
  • Sustained unresponsiveness development in wheat oral immunotherapy:
           predictive factors and flexible regimen in the maintenance phase

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. The results revealed that the reduction of 50% sIgE is a predictive factor for SU in patients with IgE-mediated wheat allergy.PMID:35620981
      DOI :10.23822/EurAnnACI.1764-1489.254 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sat, 11 Jun 2022 22:31:04 +010
       
  • Factors associated with asthma exacerbations in schoolchildren: an
           experience in clinical practice

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 May 27. doi: 10.23822/EurAnnACI.1764-1489.255. Online ahead of print.NO ABSTRACTPMID:35620992
      DOI :10.23822/EurAnnACI.1764-1489.255 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sat, 11 Jun 2022 22:31:04 +010
       
  • Sustained unresponsiveness development in wheat oral immunotherapy:
           predictive factors and flexible regimen in the maintenance phase

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. The results revealed that the reduction of 50% sIgE is a predictive factor for SU in patients with IgE-mediated wheat allergy.PMID:35620981
      DOI :10.23822/EurAnnACI.1764-1489.254 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sat, 11 Jun 2022 22:31:04 +010
       
  • Factors associated with asthma exacerbations in schoolchildren: an
           experience in clinical practice

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 May 27. doi: 10.23822/EurAnnACI.1764-1489.255. Online ahead of print.NO ABSTRACTPMID:35620992
      DOI :10.23822/EurAnnACI.1764-1489.255 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sat, 11 Jun 2022 22:31:04 +010
       
  • Sustained unresponsiveness development in wheat oral immunotherapy:
           predictive factors and flexible regimen in the maintenance phase

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. The results revealed that the reduction of 50% sIgE is a predictive factor for SU in patients with IgE-mediated wheat allergy.PMID:35620981
      DOI :10.23822/EurAnnACI.1764-1489.254 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Mon, 06 Jun 2022 05:59:13 +010
       
  • Factors associated with asthma exacerbations in schoolchildren: an
           experience in clinical practice

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 May 27. doi: 10.23822/EurAnnACI.1764-1489.255. Online ahead of print.NO ABSTRACTPMID:35620992
      DOI :10.23822/EurAnnACI.1764-1489.255 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Mon, 06 Jun 2022 05:59:13 +010
       
  • Sustained unresponsiveness development in wheat oral immunotherapy:
           predictive factors and flexible regimen in the maintenance phase

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. The results revealed that the reduction of 50% sIgE is a predictive factor for SU in patients with IgE-mediated wheat allergy.PMID:35620981
      DOI :10.23822/EurAnnACI.1764-1489.254 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Mon, 06 Jun 2022 05:59:13 +010
       
  • Factors associated with asthma exacerbations in schoolchildren: an
           experience in clinical practice

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 May 27. doi: 10.23822/EurAnnACI.1764-1489.255. Online ahead of print.NO ABSTRACTPMID:35620992
      DOI :10.23822/EurAnnACI.1764-1489.255 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Mon, 06 Jun 2022 05:59:13 +010
       
  • Sustained unresponsiveness development in wheat oral immunotherapy:
           predictive factors and flexible regimen in the maintenance phase

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. The results revealed that the reduction of 50% sIgE is a predictive factor for SU in patients with IgE-mediated wheat allergy.PMID:35620981
      DOI :10.23822/EurAnnACI.1764-1489.254 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Mon, 06 Jun 2022 05:59:13 +010
       
  • Factors associated with asthma exacerbations in schoolchildren: an
           experience in clinical practice

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 May 27. doi: 10.23822/EurAnnACI.1764-1489.255. Online ahead of print.NO ABSTRACTPMID:35620992
      DOI :10.23822/EurAnnACI.1764-1489.255 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Mon, 06 Jun 2022 05:59:13 +010
       
  • Sustained unresponsiveness development in wheat oral immunotherapy:
           predictive factors and flexible regimen in the maintenance phase

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. The results revealed that the reduction of 50% sIgE is a predictive factor for SU in patients with IgE-mediated wheat allergy.PMID:35620981
      DOI :10.23822/EurAnnACI.1764-1489.254 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Mon, 06 Jun 2022 05:59:13 +010
       
  • Factors associated with asthma exacerbations in schoolchildren: an
           experience in clinical practice

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 May 27. doi: 10.23822/EurAnnACI.1764-1489.255. Online ahead of print.NO ABSTRACTPMID:35620992
      DOI :10.23822/EurAnnACI.1764-1489.255 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Mon, 06 Jun 2022 05:59:13 +010
       
  • Sustained unresponsiveness development in wheat oral immunotherapy:
           predictive factors and flexible regimen in the maintenance phase

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. The results revealed that the reduction of 50% sIgE is a predictive factor for SU in patients with IgE-mediated wheat allergy.PMID:35620981
      DOI :10.23822/EurAnnACI.1764-1489.254 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Tue, 31 May 2022 13:08:13 +010
       
  • Factors associated with asthma exacerbations in schoolchildren: an
           experience in clinical practice

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 May 27. doi: 10.23822/EurAnnACI.1764-1489.255. Online ahead of print.NO ABSTRACTPMID:35620992
      DOI :10.23822/EurAnnACI.1764-1489.255 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Tue, 31 May 2022 13:08:13 +010
       
  • Sustained unresponsiveness development in wheat oral immunotherapy:
           predictive factors and flexible regimen in the maintenance phase

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. The results revealed that the reduction of 50% sIgE is a predictive factor for SU in patients with IgE-mediated wheat allergy.PMID:35620981
      DOI :10.23822/EurAnnACI.1764-1489.254 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Tue, 31 May 2022 13:08:13 +010
       
  • Factors associated with asthma exacerbations in schoolchildren: an
           experience in clinical practice

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 May 27. doi: 10.23822/EurAnnACI.1764-1489.255. Online ahead of print.NO ABSTRACTPMID:35620992
      DOI :10.23822/EurAnnACI.1764-1489.255 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Tue, 31 May 2022 13:08:13 +010
       
  • Sustained unresponsiveness development in wheat oral immunotherapy:
           predictive factors and flexible regimen in the maintenance phase

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. The results revealed that the reduction of 50% sIgE is a predictive factor for SU in patients with IgE-mediated wheat allergy.PMID:35620981
      DOI :10.23822/EurAnnACI.1764-1489.254 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Tue, 31 May 2022 13:08:13 +010
       
  • Factors associated with asthma exacerbations in schoolchildren: an
           experience in clinical practice

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 May 27. doi: 10.23822/EurAnnACI.1764-1489.255. Online ahead of print.NO ABSTRACTPMID:35620992
      DOI :10.23822/EurAnnACI.1764-1489.255 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Tue, 31 May 2022 13:08:13 +010
       
  • Is polyethylene glycol allergy a real contraindication to COVID-19 mRNA
           vaccines'

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 May 19. doi: 10.23822/EurAnnACI.1764-1489.253. Online ahead of print.NO ABSTRACTPMID:35586935
      DOI :10.23822/EurAnnACI.1764-1489.253 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Tue, 31 May 2022 13:08:13 +010
       
  • Pre-seasonal immunotherapy is effective in both monosensitized and
           polysensitized patients with allergic rhinitis

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. This study indicates that clinical improvement with pre-seasonal grass pollen immunotherapy is accompanied by important increase in specific IgG4 blocking antibodies. Furthermore, a single-allergen immunotherapy can lead to similar clinical efficacy and immunological changes in polysensitized as well as monosensitized patients with grass pollen allergy.PMID:35448936
      DOI :10.23822/EurAnnACI.1764-1489.252 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Fri, 20 May 2022 07:01:26 +010
       
  • Nodular regenerative hyperplasia in CVID patients: could low-dose oral
           glucocorticoids be part of the solution'

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Mar 18. doi: 10.23822/EurAnnACI.1764-1489.251. Online ahead of print.NO ABSTRACTPMID:35301845
      DOI :10.23822/EurAnnACI.1764-1489.251 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Mon, 25 Apr 2022 21:38:18 +010
       
  • Home administration of biological treatment in severe asthma in real-life
           experience: impact on asthma control and quality of life

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. Transition of day hospital administration of biologic treatment for severe asthma to home administration did not lead to any deterioration of asthma control or quality of life. Our results emphasized the efficacy and safety of home administration of biologic treatment and provide support on changing the paradigm of the administration of biological treatment in severe asthma.PMID:35261225
      DOI :10.23822/EurAnnACI.1764-1489.248 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Thu, 24 Mar 2022 02:42:37 +010
       
  • ConectAR: Collaborative network of patients with asthma and carers
           actively involved in health research. A protocol for patient and public
           involvement

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Mar 10. doi: 10.23822/EurAnnACI.1764-1489.249. Online ahead of print.ABSTRACTPatients and Public Involvement in every stage of the patient-centred health research cycle is the key to the development of innovative solutions with an impact on patients' care. This protocol describes the development of ConectAR, a network to promote the involvement of patients with asthma and their carers in the health research cycle. This protocol comprehends 4 tasks: 1) define the mission, vision, governance and activities of the network through focus groups; 2) establish the communication strategy and tools; 3) test the feasibility of the network in a Delphi study on the research priorities for asthma in Portugal; and 4) coordination and dissemination activities. This netw...
      PubDate: Thu, 24 Mar 2022 02:42:37 +010
      DOI: 10.23822/eurannaci.1764-1489.249. online ahead of print.abstractpatients and public involvement in e
       
  • Prospective study of consecutive patch testing in patients with contact
           dermatitis using an adapted Latin American baseline series

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. This study demonstrated a detailed profile of a population with suspected allergic contact dermatitis. Our patch test results, using an adapted Latin American baseline series, represent a significant update of this important diagnostic tool.PMID:35261227
      DOI :10.23822/EurAnnACI.1764-1489.250 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Thu, 24 Mar 2022 02:42:37 +010
       
  • Home administration of biological treatment in severe asthma in real-life
           experience: impact on asthma control and quality of life

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. Transition of day hospital administration of biologic treatment for severe asthma to home administration did not lead to any deterioration of asthma control or quality of life. Our results emphasized the efficacy and safety of home administration of biologic treatment and provide support on changing the paradigm of the administration of biological treatment in severe asthma.PMID:35261225
      DOI :10.23822/EurAnnACI.1764-1489.248 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Thu, 24 Mar 2022 02:42:37 +010
       
  • ConectAR: Collaborative network of patients with asthma and carers
           actively involved in health research. A protocol for patient and public
           involvement

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Mar 10. doi: 10.23822/EurAnnACI.1764-1489.249. Online ahead of print.ABSTRACTPatients and Public Involvement in every stage of the patient-centred health research cycle is the key to the development of innovative solutions with an impact on patients' care. This protocol describes the development of ConectAR, a network to promote the involvement of patients with asthma and their carers in the health research cycle. This protocol comprehends 4 tasks: 1) define the mission, vision, governance and activities of the network through focus groups; 2) establish the communication strategy and tools; 3) test the feasibility of the network in a Delphi study on the research priorities for asthma in Portugal; and 4) coordination and dissemination activities. This netw...
      PubDate: Thu, 24 Mar 2022 02:42:37 +010
      DOI: 10.23822/eurannaci.1764-1489.249. online ahead of print.abstractpatients and public involvement in e
       
  • Prospective study of consecutive patch testing in patients with contact
           dermatitis using an adapted Latin American baseline series

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. This study demonstrated a detailed profile of a population with suspected allergic contact dermatitis. Our patch test results, using an adapted Latin American baseline series, represent a significant update of this important diagnostic tool.PMID:35261227
      DOI :10.23822/EurAnnACI.1764-1489.250 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Thu, 24 Mar 2022 02:42:37 +010
       
  • Home administration of biological treatment in severe asthma in real-life
           experience: impact on asthma control and quality of life

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. Transition of day hospital administration of biologic treatment for severe asthma to home administration did not lead to any deterioration of asthma control or quality of life. Our results emphasized the efficacy and safety of home administration of biologic treatment and provide support on changing the paradigm of the administration of biological treatment in severe asthma.PMID:35261225
      DOI :10.23822/EurAnnACI.1764-1489.248 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Fri, 18 Mar 2022 09:33:36 +010
       
  • ConectAR: Collaborative network of patients with asthma and carers
           actively involved in health research. A protocol for patient and public
           involvement

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Mar 10. doi: 10.23822/EurAnnACI.1764-1489.249. Online ahead of print.ABSTRACTPatients and Public Involvement in every stage of the patient-centred health research cycle is the key to the development of innovative solutions with an impact on patients' care. This protocol describes the development of ConectAR, a network to promote the involvement of patients with asthma and their carers in the health research cycle. This protocol comprehends 4 tasks: 1) define the mission, vision, governance and activities of the network through focus groups; 2) establish the communication strategy and tools; 3) test the feasibility of the network in a Delphi study on the research priorities for asthma in Portugal; and 4) coordination and dissemination activities. This netw...
      PubDate: Fri, 18 Mar 2022 09:33:36 +010
      DOI: 10.23822/eurannaci.1764-1489.249. online ahead of print.abstractpatients and public involvement in e
       
  • Prospective study of consecutive patch testing in patients with contact
           dermatitis using an adapted Latin American baseline series

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. This study demonstrated a detailed profile of a population with suspected allergic contact dermatitis. Our patch test results, using an adapted Latin American baseline series, represent a significant update of this important diagnostic tool.PMID:35261227
      DOI :10.23822/EurAnnACI.1764-1489.250 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Fri, 18 Mar 2022 09:33:36 +010
       
  • Home administration of biological treatment in severe asthma in real-life
           experience: impact on asthma control and quality of life

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. Transition of day hospital administration of biologic treatment for severe asthma to home administration did not lead to any deterioration of asthma control or quality of life. Our results emphasized the efficacy and safety of home administration of biologic treatment and provide support on changing the paradigm of the administration of biological treatment in severe asthma.PMID:35261225
      DOI :10.23822/EurAnnACI.1764-1489.248 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Fri, 18 Mar 2022 09:33:36 +010
       
  • ConectAR: Collaborative network of patients with asthma and carers
           actively involved in health research. A protocol for patient and public
           involvement

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Mar 10. doi: 10.23822/EurAnnACI.1764-1489.249. Online ahead of print.ABSTRACTPatients and Public Involvement in every stage of the patient-centred health research cycle is the key to the development of innovative solutions with an impact on patients' care. This protocol describes the development of ConectAR, a network to promote the involvement of patients with asthma and their carers in the health research cycle. This protocol comprehends 4 tasks: 1) define the mission, vision, governance and activities of the network through focus groups; 2) establish the communication strategy and tools; 3) test the feasibility of the network in a Delphi study on the research priorities for asthma in Portugal; and 4) coordination and dissemination activities. This netw...
      PubDate: Fri, 18 Mar 2022 09:33:36 +010
      DOI: 10.23822/eurannaci.1764-1489.249. online ahead of print.abstractpatients and public involvement in e
       
  • Prospective study of consecutive patch testing in patients with contact
           dermatitis using an adapted Latin American baseline series

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. This study demonstrated a detailed profile of a population with suspected allergic contact dermatitis. Our patch test results, using an adapted Latin American baseline series, represent a significant update of this important diagnostic tool.PMID:35261227
      DOI :10.23822/EurAnnACI.1764-1489.250 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Fri, 18 Mar 2022 09:33:36 +010
       
  • Home administration of biological treatment in severe asthma in real-life
           experience: impact on asthma control and quality of life

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. Transition of day hospital administration of biologic treatment for severe asthma to home administration did not lead to any deterioration of asthma control or quality of life. Our results emphasized the efficacy and safety of home administration of biologic treatment and provide support on changing the paradigm of the administration of biological treatment in severe asthma.PMID:35261225
      DOI :10.23822/EurAnnACI.1764-1489.248 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Fri, 18 Mar 2022 09:33:36 +010
       
  • ConectAR: Collaborative network of patients with asthma and carers
           actively involved in health research. A protocol for patient and public
           involvement

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Mar 10. doi: 10.23822/EurAnnACI.1764-1489.249. Online ahead of print.ABSTRACTPatients and Public Involvement in every stage of the patient-centred health research cycle is the key to the development of innovative solutions with an impact on patients' care. This protocol describes the development of ConectAR, a network to promote the involvement of patients with asthma and their carers in the health research cycle. This protocol comprehends 4 tasks: 1) define the mission, vision, governance and activities of the network through focus groups; 2) establish the communication strategy and tools; 3) test the feasibility of the network in a Delphi study on the research priorities for asthma in Portugal; and 4) coordination and dissemination activities. This netw...
      PubDate: Fri, 18 Mar 2022 09:33:36 +010
      DOI: 10.23822/eurannaci.1764-1489.249. online ahead of print.abstractpatients and public involvement in e
       
  • Prospective study of consecutive patch testing in patients with contact
           dermatitis using an adapted Latin American baseline series

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. This study demonstrated a detailed profile of a population with suspected allergic contact dermatitis. Our patch test results, using an adapted Latin American baseline series, represent a significant update of this important diagnostic tool.PMID:35261227
      DOI :10.23822/EurAnnACI.1764-1489.250 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Fri, 18 Mar 2022 09:33:36 +010
       
  • Home administration of biological treatment in severe asthma in real-life
           experience: impact on asthma control and quality of life

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. Transition of day hospital administration of biologic treatment for severe asthma to home administration did not lead to any deterioration of asthma control or quality of life. Our results emphasized the efficacy and safety of home administration of biologic treatment and provide support on changing the paradigm of the administration of biological treatment in severe asthma.PMID:35261225
      DOI :10.23822/EurAnnACI.1764-1489.248 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Mon, 14 Mar 2022 02:29:47 +010
       
  • ConectAR: Collaborative network of patients with asthma and carers
           actively involved in health research. A protocol for patient and public
           involvement

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Mar 10. doi: 10.23822/EurAnnACI.1764-1489.249. Online ahead of print.ABSTRACTPatients and Public Involvement in every stage of the patient-centred health research cycle is the key to the development of innovative solutions with an impact on patients' care. This protocol describes the development of ConectAR, a network to promote the involvement of patients with asthma and their carers in the health research cycle. This protocol comprehends 4 tasks: 1) define the mission, vision, governance and activities of the network through focus groups; 2) establish the communication strategy and tools; 3) test the feasibility of the network in a Delphi study on the research priorities for asthma in Portugal; and 4) coordination and dissemination activities. This netw...
      PubDate: Mon, 14 Mar 2022 02:29:47 +010
      DOI: 10.23822/eurannaci.1764-1489.249. online ahead of print.abstractpatients and public involvement in e
       
  • Prospective study of consecutive patch testing in patients with contact
           dermatitis using an adapted Latin American baseline series

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. This study demonstrated a detailed profile of a population with suspected allergic contact dermatitis. Our patch test results, using an adapted Latin American baseline series, represent a significant update of this important diagnostic tool.PMID:35261227
      DOI :10.23822/EurAnnACI.1764-1489.250 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Mon, 14 Mar 2022 02:29:47 +010
       
  • Home administration of biological treatment in severe asthma in real-life
           experience: impact on asthma control and quality of life

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. Transition of day hospital administration of biologic treatment for severe asthma to home administration did not lead to any deterioration of asthma control or quality of life. Our results emphasized the efficacy and safety of home administration of biologic treatment and provide support on changing the paradigm of the administration of biological treatment in severe asthma.PMID:35261225
      DOI :10.23822/EurAnnACI.1764-1489.248 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Mon, 14 Mar 2022 02:29:47 +010
       
  • ConectAR: Collaborative network of patients with asthma and carers
           actively involved in health research. A protocol for patient and public
           involvement

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Mar 10. doi: 10.23822/EurAnnACI.1764-1489.249. Online ahead of print.ABSTRACTPatients and Public Involvement in every stage of the patient-centred health research cycle is the key to the development of innovative solutions with an impact on patients' care. This protocol describes the development of ConectAR, a network to promote the involvement of patients with asthma and their carers in the health research cycle. This protocol comprehends 4 tasks: 1) define the mission, vision, governance and activities of the network through focus groups; 2) establish the communication strategy and tools; 3) test the feasibility of the network in a Delphi study on the research priorities for asthma in Portugal; and 4) coordination and dissemination activities. This netw...
      PubDate: Mon, 14 Mar 2022 02:29:47 +010
      DOI: 10.23822/eurannaci.1764-1489.249. online ahead of print.abstractpatients and public involvement in e
       
  • Prospective study of consecutive patch testing in patients with contact
           dermatitis using an adapted Latin American baseline series

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. This study demonstrated a detailed profile of a population with suspected allergic contact dermatitis. Our patch test results, using an adapted Latin American baseline series, represent a significant update of this important diagnostic tool.PMID:35261227
      DOI :10.23822/EurAnnACI.1764-1489.250 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Mon, 14 Mar 2022 02:29:47 +010
       
  • Home administration of biological treatment in severe asthma in real-life
           experience: impact on asthma control and quality of life

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. Transition of day hospital administration of biologic treatment for severe asthma to home administration did not lead to any deterioration of asthma control or quality of life. Our results emphasized the efficacy and safety of home administration of biologic treatment and provide support on changing the paradigm of the administration of biological treatment in severe asthma.PMID:35261225
      DOI :10.23822/EurAnnACI.1764-1489.248 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Mon, 14 Mar 2022 02:29:47 +010
       
  • ConectAR: Collaborative network of patients with asthma and carers
           actively involved in health research. A protocol for patient and public
           involvement

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Mar 10. doi: 10.23822/EurAnnACI.1764-1489.249. Online ahead of print.ABSTRACTPatients and Public Involvement in every stage of the patient-centred health research cycle is the key to the development of innovative solutions with an impact on patients' care. This protocol describes the development of ConectAR, a network to promote the involvement of patients with asthma and their carers in the health research cycle. This protocol comprehends 4 tasks: 1) define the mission, vision, governance and activities of the network through focus groups; 2) establish the communication strategy and tools; 3) test the feasibility of the network in a Delphi study on the research priorities for asthma in Portugal; and 4) coordination and dissemination activities. This netw...
      PubDate: Mon, 14 Mar 2022 02:29:47 +010
      DOI: 10.23822/eurannaci.1764-1489.249. online ahead of print.abstractpatients and public involvement in e
       
  • Prospective study of consecutive patch testing in patients with contact
           dermatitis using an adapted Latin American baseline series

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. This study demonstrated a detailed profile of a population with suspected allergic contact dermatitis. Our patch test results, using an adapted Latin American baseline series, represent a significant update of this important diagnostic tool.PMID:35261227
      DOI :10.23822/EurAnnACI.1764-1489.250 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Mon, 14 Mar 2022 02:29:47 +010
       
  • Iodinated contrast media hypersensitivity reactions: is it time to
           re-evaluate risk factors'

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Mar;54(2):51-52. doi: 10.23822/EurAnnACI.1764-1489.245.NO ABSTRACTPMID:35227039
      DOI :10.23822/EurAnnACI.1764-1489.245 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Mon, 14 Mar 2022 02:29:47 +010
       
  • Eosinophilic pneumonia following Sinovac/CoronaVac vaccination

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Feb 25. Online ahead of print.NO ABSTRACTPMID:35212215 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Tue, 08 Mar 2022 10:46:48 +010
       
  • Hypersentivity reactions to COVID-19 vaccines: a case of Eosinophilic
           pneumonia following Sinovac/CoronaVac vaccination

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Feb 11. doi: 10.23822/EurAnnACI.1764-1489.247. Online ahead of print.ABSTRACTHypersensitivity reactions has been reported with COVID-19 vaccines. Acute eosinophilic pneumonia has not been reported yet after Sinovac/CoronaVac vaccine. A 73-year-old woman presented with maculopapular rash, cough and dyspnea following Sinovac/CoronaVac injection. The complete blood count (CBC) indicated eosinophilia and further evaluation of the eosinophilia with CT and bronchoscopy confirmed a diagnosis of acute eosinophilic pneumonia. After methylprednisolone therapy, her rash resolved with marked improvement of the dyspnea. She is still on treatment and on the follow up period, we plan to continue steroid treatment at least 3 months.PMID:35156356
      DOI :10.23822/EurAnnACI....
      PubDate: Tue, 01 Mar 2022 08:26:10 +010
       
  • Anaphylaxis reaction to samsum ant (Pachycondyla sennaarensis): a Case
           Series Study

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. Ant sting anaphylaxis is not uncommon in Iran, especially in its southern regions. All cases of anaphylaxis in this study were due to samsum ant sting (Pachycondyla sennaarensis), which is a species similar to the fire ant (Solenopsis invicta). Allergy skin testing with fire ant extract was positive and helpful in identifying samsum ant allergy in all cases.PMID:35156357
      DOI :10.23822/EurAnnACI.1764-1489.246 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Tue, 01 Mar 2022 08:26:10 +010
       
  • Hypersentivity reactions to COVID-19 vaccines: a case of Eosinophilic
           pneumonia following Sinovac/CoronaVac vaccination

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Feb 11. doi: 10.23822/EurAnnACI.1764-1489.247. Online ahead of print.ABSTRACTHypersensitivity reactions has been reported with COVID-19 vaccines. Acute eosinophilic pneumonia has not been reported yet after Sinovac/CoronaVac vaccine. A 73-year-old woman presented with maculopapular rash, cough and dyspnea following Sinovac/CoronaVac injection. The complete blood count (CBC) indicated eosinophilia and further evaluation of the eosinophilia with CT and bronchoscopy confirmed a diagnosis of acute eosinophilic pneumonia. After methylprednisolone therapy, her rash resolved with marked improvement of the dyspnea. She is still on treatment and on the follow up period, we plan to continue steroid treatment at least 3 months.PMID:35156356
      DOI :10.23822/EurAnnACI....
      PubDate: Tue, 01 Mar 2022 08:26:10 +010
       
  • Anaphylaxis reaction to samsum ant (Pachycondyla sennaarensis): a Case
           Series Study

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. Ant sting anaphylaxis is not uncommon in Iran, especially in its southern regions. All cases of anaphylaxis in this study were due to samsum ant sting (Pachycondyla sennaarensis), which is a species similar to the fire ant (Solenopsis invicta). Allergy skin testing with fire ant extract was positive and helpful in identifying samsum ant allergy in all cases.PMID:35156357
      DOI :10.23822/EurAnnACI.1764-1489.246 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Tue, 01 Mar 2022 08:26:10 +010
       
  • Hypersentivity reactions to COVID-19 vaccines: a case of Eosinophilic
           pneumonia following Sinovac/CoronaVac vaccination

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Feb 11. doi: 10.23822/EurAnnACI.1764-1489.247. Online ahead of print.ABSTRACTHypersensitivity reactions has been reported with COVID-19 vaccines. Acute eosinophilic pneumonia has not been reported yet after Sinovac/CoronaVac vaccine. A 73-year-old woman presented with maculopapular rash, cough and dyspnea following Sinovac/CoronaVac injection. The complete blood count (CBC) indicated eosinophilia and further evaluation of the eosinophilia with CT and bronchoscopy confirmed a diagnosis of acute eosinophilic pneumonia. After methylprednisolone therapy, her rash resolved with marked improvement of the dyspnea. She is still on treatment and on the follow up period, we plan to continue steroid treatment at least 3 months.PMID:35156356
      DOI :10.23822/EurAnnACI....
      PubDate: Wed, 23 Feb 2022 16:00:10 +010
       
  • Anaphylaxis reaction to samsum ant (Pachycondyla sennaarensis): a Case
           Series Study

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. Ant sting anaphylaxis is not uncommon in Iran, especially in its southern regions. All cases of anaphylaxis in this study were due to samsum ant sting (Pachycondyla sennaarensis), which is a species similar to the fire ant (Solenopsis invicta). Allergy skin testing with fire ant extract was positive and helpful in identifying samsum ant allergy in all cases.PMID:35156357
      DOI :10.23822/EurAnnACI.1764-1489.246 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Wed, 23 Feb 2022 16:00:10 +010
       
  • Hypersentivity reactions to COVID-19 vaccines: a case of Eosinophilic
           pneumonia following Sinovac/CoronaVac vaccination

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Feb 11. doi: 10.23822/EurAnnACI.1764-1489.247. Online ahead of print.ABSTRACTHypersensitivity reactions has been reported with COVID-19 vaccines. Acute eosinophilic pneumonia has not been reported yet after Sinovac/CoronaVac vaccine. A 73-year-old woman presented with maculopapular rash, cough and dyspnea following Sinovac/CoronaVac injection. The complete blood count (CBC) indicated eosinophilia and further evaluation of the eosinophilia with CT and bronchoscopy confirmed a diagnosis of acute eosinophilic pneumonia. After methylprednisolone therapy, her rash resolved with marked improvement of the dyspnea. She is still on treatment and on the follow up period, we plan to continue steroid treatment at least 3 months.PMID:35156356
      DOI :10.23822/EurAnnACI....
      PubDate: Wed, 23 Feb 2022 16:00:10 +010
       
  • Anaphylaxis reaction to samsum ant (Pachycondyla sennaarensis): a Case
           Series Study

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. Ant sting anaphylaxis is not uncommon in Iran, especially in its southern regions. All cases of anaphylaxis in this study were due to samsum ant sting (Pachycondyla sennaarensis), which is a species similar to the fire ant (Solenopsis invicta). Allergy skin testing with fire ant extract was positive and helpful in identifying samsum ant allergy in all cases.PMID:35156357
      DOI :10.23822/EurAnnACI.1764-1489.246 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Wed, 23 Feb 2022 16:00:10 +010
       
  • Hypersentivity reactions to COVID-19 vaccines: a case of Eosinophilic
           pneumonia following Sinovac/CoronaVac vaccination

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Feb 11. doi: 10.23822/EurAnnACI.1764-1489.247. Online ahead of print.ABSTRACTHypersensitivity reactions has been reported with COVID-19 vaccines. Acute eosinophilic pneumonia has not been reported yet after Sinovac/CoronaVac vaccine. A 73-year-old woman presented with maculopapular rash, cough and dyspnea following Sinovac/CoronaVac injection. The complete blood count (CBC) indicated eosinophilia and further evaluation of the eosinophilia with CT and bronchoscopy confirmed a diagnosis of acute eosinophilic pneumonia. After methylprednisolone therapy, her rash resolved with marked improvement of the dyspnea. She is still on treatment and on the follow up period, we plan to continue steroid treatment at least 3 months.PMID:35156356
      DOI :10.23822/EurAnnACI....
      PubDate: Wed, 23 Feb 2022 16:00:10 +010
       
  • Anaphylaxis reaction to samsum ant (Pachycondyla sennaarensis): a Case
           Series Study

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. Ant sting anaphylaxis is not uncommon in Iran, especially in its southern regions. All cases of anaphylaxis in this study were due to samsum ant sting (Pachycondyla sennaarensis), which is a species similar to the fire ant (Solenopsis invicta). Allergy skin testing with fire ant extract was positive and helpful in identifying samsum ant allergy in all cases.PMID:35156357
      DOI :10.23822/EurAnnACI.1764-1489.246 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Wed, 23 Feb 2022 16:00:10 +010
       
  • Hypersentivity reactions to COVID-19 vaccines: a case of Eosinophilic
           pneumonia following Sinovac/CoronaVac vaccination

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Feb 11. doi: 10.23822/EurAnnACI.1764-1489.247. Online ahead of print.ABSTRACTHypersensitivity reactions has been reported with COVID-19 vaccines. Acute eosinophilic pneumonia has not been reported yet after Sinovac/CoronaVac vaccine. A 73-year-old woman presented with maculopapular rash, cough and dyspnea following Sinovac/CoronaVac injection. The complete blood count (CBC) indicated eosinophilia and further evaluation of the eosinophilia with CT and bronchoscopy confirmed a diagnosis of acute eosinophilic pneumonia. After methylprednisolone therapy, her rash resolved with marked improvement of the dyspnea. She is still on treatment and on the follow up period, we plan to continue steroid treatment at least 3 months.PMID:35156356
      DOI :10.23822/EurAnnACI....
      PubDate: Wed, 23 Feb 2022 16:00:10 +010
       
  • Anaphylaxis reaction to samsum ant (Pachycondyla sennaarensis): a Case
           Series Study

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. Ant sting anaphylaxis is not uncommon in Iran, especially in its southern regions. All cases of anaphylaxis in this study were due to samsum ant sting (Pachycondyla sennaarensis), which is a species similar to the fire ant (Solenopsis invicta). Allergy skin testing with fire ant extract was positive and helpful in identifying samsum ant allergy in all cases.PMID:35156357
      DOI :10.23822/EurAnnACI.1764-1489.246 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Wed, 23 Feb 2022 16:00:10 +010
       
  • Hypersentivity reactions to COVID-19 vaccines: a case of Eosinophilic
           pneumonia following Sinovac/CoronaVac vaccination

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Feb 11. doi: 10.23822/EurAnnACI.1764-1489.247. Online ahead of print.ABSTRACTHypersensitivity reactions has been reported with COVID-19 vaccines. Acute eosinophilic pneumonia has not been reported yet after Sinovac/CoronaVac vaccine. A 73-year-old woman presented with maculopapular rash, cough and dyspnea following Sinovac/CoronaVac injection. The complete blood count (CBC) indicated eosinophilia and further evaluation of the eosinophilia with CT and bronchoscopy confirmed a diagnosis of acute eosinophilic pneumonia. After methylprednisolone therapy, her rash resolved with marked improvement of the dyspnea. She is still on treatment and on the follow up period, we plan to continue steroid treatment at least 3 months.PMID:35156356
      DOI :10.23822/EurAnnACI....
      PubDate: Thu, 17 Feb 2022 22:50:37 +010
       
  • Anaphylaxis reaction to samsum ant (Pachycondyla sennaarensis): a Case
           Series Study

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. Ant sting anaphylaxis is not uncommon in Iran, especially in its southern regions. All cases of anaphylaxis in this study were due to samsum ant sting (Pachycondyla sennaarensis), which is a species similar to the fire ant (Solenopsis invicta). Allergy skin testing with fire ant extract was positive and helpful in identifying samsum ant allergy in all cases.PMID:35156357
      DOI :10.23822/EurAnnACI.1764-1489.246 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Thu, 17 Feb 2022 22:50:37 +010
       
  • Hypersentivity reactions to COVID-19 vaccines: a case of Eosinophilic
           pneumonia following Sinovac/CoronaVac vaccination

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Feb 11. doi: 10.23822/EurAnnACI.1764-1489.247. Online ahead of print.ABSTRACTHypersensitivity reactions has been reported with COVID-19 vaccines. Acute eosinophilic pneumonia has not been reported yet after Sinovac/CoronaVac vaccine. A 73-year-old woman presented with maculopapular rash, cough and dyspnea following Sinovac/CoronaVac injection. The complete blood count (CBC) indicated eosinophilia and further evaluation of the eosinophilia with CT and bronchoscopy confirmed a diagnosis of acute eosinophilic pneumonia. After methylprednisolone therapy, her rash resolved with marked improvement of the dyspnea. She is still on treatment and on the follow up period, we plan to continue steroid treatment at least 3 months.PMID:35156356
      DOI :10.23822/EurAnnACI....
      PubDate: Thu, 17 Feb 2022 22:50:37 +010
       
  • Anaphylaxis reaction to samsum ant (Pachycondyla sennaarensis): a Case
           Series Study

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. Ant sting anaphylaxis is not uncommon in Iran, especially in its southern regions. All cases of anaphylaxis in this study were due to samsum ant sting (Pachycondyla sennaarensis), which is a species similar to the fire ant (Solenopsis invicta). Allergy skin testing with fire ant extract was positive and helpful in identifying samsum ant allergy in all cases.PMID:35156357
      DOI :10.23822/EurAnnACI.1764-1489.246 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Thu, 17 Feb 2022 22:50:37 +010
       
  • Hypersentivity reactions to COVID-19 vaccines: a case of Eosinophilic
           pneumonia following Sinovac/CoronaVac vaccination

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Feb 11. doi: 10.23822/EurAnnACI.1764-1489.247. Online ahead of print.ABSTRACTHypersensitivity reactions has been reported with COVID-19 vaccines. Acute eosinophilic pneumonia has not been reported yet after Sinovac/CoronaVac vaccine. A 73-year-old woman presented with maculopapular rash, cough and dyspnea following Sinovac/CoronaVac injection. The complete blood count (CBC) indicated eosinophilia and further evaluation of the eosinophilia with CT and bronchoscopy confirmed a diagnosis of acute eosinophilic pneumonia. After methylprednisolone therapy, her rash resolved with marked improvement of the dyspnea. She is still on treatment and on the follow up period, we plan to continue steroid treatment at least 3 months.PMID:35156356
      DOI :10.23822/EurAnnACI....
      PubDate: Thu, 17 Feb 2022 22:50:37 +010
       
  • Anaphylaxis reaction to samsum ant (Pachycondyla sennaarensis): a Case
           Series Study

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. Ant sting anaphylaxis is not uncommon in Iran, especially in its southern regions. All cases of anaphylaxis in this study were due to samsum ant sting (Pachycondyla sennaarensis), which is a species similar to the fire ant (Solenopsis invicta). Allergy skin testing with fire ant extract was positive and helpful in identifying samsum ant allergy in all cases.PMID:35156357
      DOI :10.23822/EurAnnACI.1764-1489.246 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Thu, 17 Feb 2022 22:50:37 +010
       
  • Atopic dermatitis in adolescents with < em> acne vulgaris < /em>

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Jan 26. doi: 10.23822/EurAnnACI.1764-1489.244. Online ahead of print.NO ABSTRACTPMID:35080170
      DOI :10.23822/EurAnnACI.1764-1489.244 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Thu, 17 Feb 2022 22:50:37 +010
       
  • Atopic dermatitis in adolescents with < em> acne vulgaris < /em>

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Jan 26. doi: 10.23822/EurAnnACI.1764-1489.244. Online ahead of print.NO ABSTRACTPMID:35080170
      DOI :10.23822/EurAnnACI.1764-1489.244 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Thu, 17 Feb 2022 22:50:37 +010
       
  • Atopic dermatitis in adolescents with < em> acne vulgaris < /em>

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Jan 26. doi: 10.23822/EurAnnACI.1764-1489.244. Online ahead of print.NO ABSTRACTPMID:35080170
      DOI :10.23822/EurAnnACI.1764-1489.244 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sat, 12 Feb 2022 05:24:42 +010
       
  • Atopic dermatitis in adolescents with < em> acne vulgaris < /em>

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Jan 26. doi: 10.23822/EurAnnACI.1764-1489.244. Online ahead of print.NO ABSTRACTPMID:35080170
      DOI :10.23822/EurAnnACI.1764-1489.244 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sat, 12 Feb 2022 05:24:42 +010
       
  • Atopic dermatitis in adolescents with < em> acne vulgaris < /em>

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Jan 26. doi: 10.23822/EurAnnACI.1764-1489.244. Online ahead of print.NO ABSTRACTPMID:35080170
      DOI :10.23822/EurAnnACI.1764-1489.244 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sat, 12 Feb 2022 05:24:42 +010
       
  • Atopic dermatitis in adolescents with < em> acne vulgaris < /em>

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Jan 26. doi: 10.23822/EurAnnACI.1764-1489.244. Online ahead of print.NO ABSTRACTPMID:35080170
      DOI :10.23822/EurAnnACI.1764-1489.244 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sat, 12 Feb 2022 05:24:42 +010
       
  • Atopic dermatitis in adolescents with < em> acne vulgaris < /em>

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Jan 26. doi: 10.23822/EurAnnACI.1764-1489.244. Online ahead of print.NO ABSTRACTPMID:35080170
      DOI :10.23822/EurAnnACI.1764-1489.244 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sat, 12 Feb 2022 05:24:42 +010
       
  • Atopic dermatitis in adolescents with < em > acne vulgaris < /em
           >

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Jan 26. doi: 10.23822/EurAnnACI.1764-1489.244. Online ahead of print.NO ABSTRACTPMID:35080170
      DOI :10.23822/EurAnnACI.1764-1489.244 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 06 Feb 2022 11:48:33 +010
       
  • Atopic dermatitis in adolescents with < em > acne vulgaris < /em
           >

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Jan 26. doi: 10.23822/EurAnnACI.1764-1489.244. Online ahead of print.NO ABSTRACTPMID:35080170
      DOI :10.23822/EurAnnACI.1764-1489.244 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 06 Feb 2022 11:48:33 +010
       
  • Atopic dermatitis in adolescents with < em > acne vulgaris < /em
           >

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Jan 26. doi: 10.23822/EurAnnACI.1764-1489.244. Online ahead of print.NO ABSTRACTPMID:35080170
      DOI :10.23822/EurAnnACI.1764-1489.244 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 06 Feb 2022 11:48:33 +010
       
  • Atopic dermatitis in adolescents with < em > acne vulgaris < /em
           >

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Jan 26. doi: 10.23822/EurAnnACI.1764-1489.244. Online ahead of print.NO ABSTRACTPMID:35080170
      DOI :10.23822/EurAnnACI.1764-1489.244 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 06 Feb 2022 11:48:33 +010
       
  • Atopic dermatitis in adolescents with < em> acne vulgaris < /em>

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Jan 26. doi: 10.23822/EurAnnACI.1764-1489.244. Online ahead of print.NO ABSTRACTPMID:35080170
      DOI :10.23822/EurAnnACI.1764-1489.244 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 30 Jan 2022 05:55:33 +010
       
  • Atopic dermatitis in adolescents with < em> acne vulgaris < /em>

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2022 Jan 26. doi: 10.23822/EurAnnACI.1764-1489.244. Online ahead of print.NO ABSTRACTPMID:35080170
      DOI :10.23822/EurAnnACI.1764-1489.244 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 30 Jan 2022 05:55:33 +010
       
  • Qualitative and quantitative comparison of allergen component-specific to
           birch and grass analyzed by ImmunoCAP assay and Euroline immunoblot test

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. Overall, we found that there is good correlation between the Euroline and ImmunoCAP methods in measuring IgE sensitization.PMID:35029100
      DOI :10.23822/EurAnnACI.1764-1489.241 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 30 Jan 2022 05:55:33 +010
       
  • Isn't it time to consider oncological status as a new risk factor of
           iodinated contrast media hypersensitivity'

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. A high proportion of oncological patients was observed in our population with HS to ICM. They did not have other known risk factors, and they were less atopic. Larger multicentric studies should explore cancer as a potential new risk factor.PMID:35029101
      DOI :10.23822/EurAnnACI.1764-1489.242 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 30 Jan 2022 05:55:33 +010
       
  • Qualitative and quantitative comparison of allergen component-specific to
           birch and grass analyzed by ImmunoCAP assay and Euroline immunoblot test

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. Overall, we found that there is good correlation between the Euroline and ImmunoCAP methods in measuring IgE sensitization.PMID:35029100
      DOI :10.23822/EurAnnACI.1764-1489.241 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 30 Jan 2022 05:55:33 +010
       
  • Isn't it time to consider oncological status as a new risk factor of
           iodinated contrast media hypersensitivity'

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. A high proportion of oncological patients was observed in our population with HS to ICM. They did not have other known risk factors, and they were less atopic. Larger multicentric studies should explore cancer as a potential new risk factor.PMID:35029101
      DOI :10.23822/EurAnnACI.1764-1489.242 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 30 Jan 2022 05:55:33 +010
       
  • Qualitative and quantitative comparison of allergen component-specific to
           birch and grass analyzed by ImmunoCAP assay and Euroline immunoblot test

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. Overall, we found that there is good correlation between the Euroline and ImmunoCAP methods in measuring IgE sensitization.PMID:35029100
      DOI :10.23822/EurAnnACI.1764-1489.241 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 30 Jan 2022 05:55:33 +010
       
  • Isn't it time to consider oncological status as a new risk factor of
           iodinated contrast media hypersensitivity'

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. A high proportion of oncological patients was observed in our population with HS to ICM. They did not have other known risk factors, and they were less atopic. Larger multicentric studies should explore cancer as a potential new risk factor.PMID:35029101
      DOI :10.23822/EurAnnACI.1764-1489.242 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 30 Jan 2022 05:55:33 +010
       
  • Qualitative and quantitative comparison of allergen component-specific to
           birch and grass analyzed by ImmunoCAP assay and Euroline immunoblot test

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. Overall, we found that there is good correlation between the Euroline and ImmunoCAP methods in measuring IgE sensitization.PMID:35029100
      DOI :10.23822/EurAnnACI.1764-1489.241 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 30 Jan 2022 05:55:33 +010
       
  • Isn't it time to consider oncological status as a new risk factor of
           iodinated contrast media hypersensitivity'

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. A high proportion of oncological patients was observed in our population with HS to ICM. They did not have other known risk factors, and they were less atopic. Larger multicentric studies should explore cancer as a potential new risk factor.PMID:35029101
      DOI :10.23822/EurAnnACI.1764-1489.242 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 30 Jan 2022 05:55:33 +010
       
  • Qualitative and quantitative comparison of allergen component-specific to
           birch and grass analyzed by ImmunoCAP assay and Euroline immunoblot test

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. Overall, we found that there is good correlation between the Euroline and ImmunoCAP methods in measuring IgE sensitization.PMID:35029100
      DOI :10.23822/EurAnnACI.1764-1489.241 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 30 Jan 2022 05:55:33 +010
       
  • Isn't it time to consider oncological status as a new risk factor of
           iodinated contrast media hypersensitivity'

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. A high proportion of oncological patients was observed in our population with HS to ICM. They did not have other known risk factors, and they were less atopic. Larger multicentric studies should explore cancer as a potential new risk factor.PMID:35029101
      DOI :10.23822/EurAnnACI.1764-1489.242 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 30 Jan 2022 05:55:33 +010
       
  • Cost-effectiveness analysis of grass pollen specific immunotherapy in
           children with allergic rhinitis compared to the standard of care
           symptomatic treatment in Portugal

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. AIT is cost-effective in children with grass pollen allergic rhinitis, especially for the subcutaneous route.PMID:34927406
      DOI :10.23822/EurAnnACI.1764-1489.240 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Sun, 30 Jan 2022 05:55:33 +010
       
  • The spectrum of inborn errors of immunity: a single tertiary center
           retrospective study in Alborz, Iran

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. IEIs have different patterns within populations with high consanguinity. There is a need to search for underlying genetic and epigenetic factors in most common IEIs in Alborz.PMID:34918886
      DOI :10.23822/EurAnnACI.1764-1489.239 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Fri, 17 Dec 2021 11:00:00 +010
       
  • 35 years of autologous serum skin test in chronic spontaneous urticaria:
           what we know and what we do not know

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: This article will review our current knowledge about the clinical significance of the ASST and the factors possibly associated with the occurrence of the skin reaction following the intradermal administration of autologous serum that are known so far.PMID:34904801
      DOI :10.23822/EurAnnACI.1764-1489.238 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Tue, 14 Dec 2021 11:00:00 +010
       
  • Effects of elimination diets and clinical findings on mothers' anxiety in
           infants with food allergy with non-life-threatening reactions

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. The state anxiety and trait anxiety of the mothers of the infants with FA were higher than the control group, and the state anxiety scores were higher especially in the mothers of infants with FPIAP and multiple food elimination.PMID:34797040
      DOI :10.23822/EurAnnACI.1764-1489.237 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Fri, 19 Nov 2021 11:00:00 +010
       
  • Failure of desensitization with Pfizer-BioNTech COVID-19 vaccine in two
           asthmatic patients

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2021 Nov 5. doi: 10.23822/EurAnnACI.1764-1489.236. Online ahead of print.NO ABSTRACTPMID:34753281
      DOI :10.23822/EurAnnACI.1764-1489.236 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Wed, 10 Nov 2021 11:00:00 +010
       
  • The gender effect in children and adolescents with asthma: practical
           outcomes from the "ControL'Asma" study

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2021 Oct 6. doi: 10.23822/EurAnnACI.1764-1489.235. Online ahead of print.NO ABSTRACTPMID:34612027
      DOI :10.23822/EurAnnACI.1764-1489.235 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Wed, 06 Oct 2021 10:00:00 +010
       
  • Patient Reported Outcomes in allergic diseases: findings and implications

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2021 Sep;53(5):199-200. doi: 10.23822/EurAnnACI.1764-1489.232.NO ABSTRACTPMID:34525790
      DOI :10.23822/EurAnnACI.1764-1489.232 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Thu, 16 Sep 2021 10:00:00 +010
       
  • Anaphylactic shock to iodinated contrast media: not so rare after all

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2021 Sep 15. doi: 10.23822/EurAnnACI.1764-1489.210. Online ahead of print.NO ABSTRACTPMID:34523871
      DOI :10.23822/EurAnnACI.1764-1489.210 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Wed, 15 Sep 2021 10:00:00 +010
       
  • Pilot study: specific immunotherapy in patients with Papular urticaria by
           Cimex lectularius

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. Patients with papular urticaria by Cimex lectularius receiving allergen immunotherapy for 1 year showed a significant improvement compared with baseline and patients receiving conventional treatment regarding skin lesions, quality of life impairment, intensity of pruritus and satisfaction with immunotherapy.PMID:34523872
      DOI :10.23822/EurAnnACI.1764-1489.215 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Wed, 15 Sep 2021 10:00:00 +010
       
  • Anaphylactic shock to iodinated contrast media: not so rare after all

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2021 Sep 15. doi: 10.23822/EurAnnACI.1764-1489.210. Online ahead of print.NO ABSTRACTPMID:34523871
      DOI :10.23822/EurAnnACI.1764-1489.210 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Wed, 15 Sep 2021 10:00:00 +010
       
  • Pilot study: specific immunotherapy in patients with Papular urticaria by
           Cimex lectularius

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. Patients with papular urticaria by Cimex lectularius receiving allergen immunotherapy for 1 year showed a significant improvement compared with baseline and patients receiving conventional treatment regarding skin lesions, quality of life impairment, intensity of pruritus and satisfaction with immunotherapy.PMID:34523872
      DOI :10.23822/EurAnnACI.1764-1489.215 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Wed, 15 Sep 2021 10:00:00 +010
       
  • Asthma and COVID-19 pandemic: focused on the eosinophil count and ACE2
           expression

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2021 Sep 10. doi: 10.23822/EurAnnACI.1764-1489.233. Online ahead of print.ABSTRACTCurrently, the world is engaged with a coronavirus disease 2019 (COVID-19) caused by acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection. The Center for Disease Control and Prevention (CDC) has proposed moderate to severe asthma as a risk factor for COVID-19 susceptibility and severity. However, current evidences have not identified asthma in the top 10 comorbidities associated with COVID-19 fatalities. It raises the question that why patients with different type of asthma are not more vulnerable to SARS-CoV-2 infection like other respiratory infection. Increased number of eosinophils and elevated angiotensin-converting enzyme 2 (ACE2) expressions in asthma are suppos...
      PubDate: Fri, 10 Sep 2021 10:00:00 +010
      DOI: 10.23822/eurannaci.1764-1489.233. online ahead of print.abstractcurrently, the world is engaged with
       
  • Allergic rhinitis and COVID-19: friends or foes'

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2021 Sep 10. doi: 10.23822/EurAnnACI.1764-1489.234. Online ahead of print.ABSTRACTAllergic rhinitis (AR) is a common disease affecting up to 40% of the general population worldwide. In the Coronavirus 2019 (COVID-19) pandemic era, many observational studies analysing the effect of asthma and chronic obstructive pulmonary disease on the risk of developing COVID-19 were conducted, while data on AR are limited.In this paper, we review the risk of developing SARS-Cov-2 infection carried by AR patients, the outcomes of those with COVID-19 disease, and the COVID-19 influence on the allergic and nasal symptoms and the psychological status of AR patients, in both adult and paediatric populations.AR patients seem to be protected from COVID 19 infection. Even if data ab...
      PubDate: Fri, 10 Sep 2021 10:00:00 +010
      DOI: 10.23822/eurannaci.1764-1489.234. online ahead of print.abstractallergic rhinitis (ar) is a common d
       
  • Asthma and COVID-19 pandemic: focused on the eosinophil count and ACE2
           expression

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2021 Sep 10. doi: 10.23822/EurAnnACI.1764-1489.233. Online ahead of print.ABSTRACTCurrently, the world is engaged with a coronavirus disease 2019 (COVID-19) caused by acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection. The Center for Disease Control and Prevention (CDC) has proposed moderate to severe asthma as a risk factor for COVID-19 susceptibility and severity. However, current evidences have not identified asthma in the top 10 comorbidities associated with COVID-19 fatalities. It raises the question that why patients with different type of asthma are not more vulnerable to SARS-CoV-2 infection like other respiratory infection. Increased number of eosinophils and elevated angiotensin-converting enzyme 2 (ACE2) expressions in asthma are suppos...
      PubDate: Fri, 10 Sep 2021 10:00:00 +010
      DOI: 10.23822/eurannaci.1764-1489.233. online ahead of print.abstractcurrently, the world is engaged with
       
  • Allergic rhinitis and COVID-19: friends or foes'

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2021 Sep 10. doi: 10.23822/EurAnnACI.1764-1489.234. Online ahead of print.ABSTRACTAllergic rhinitis (AR) is a common disease affecting up to 40% of the general population worldwide. In the Coronavirus 2019 (COVID-19) pandemic era, many observational studies analysing the effect of asthma and chronic obstructive pulmonary disease on the risk of developing COVID-19 were conducted, while data on AR are limited.In this paper, we review the risk of developing SARS-Cov-2 infection carried by AR patients, the outcomes of those with COVID-19 disease, and the COVID-19 influence on the allergic and nasal symptoms and the psychological status of AR patients, in both adult and paediatric populations.AR patients seem to be protected from COVID 19 infection. Even if data ab...
      PubDate: Fri, 10 Sep 2021 10:00:00 +010
      DOI: 10.23822/eurannaci.1764-1489.234. online ahead of print.abstractallergic rhinitis (ar) is a common d
       
  • Asthma and COVID-19 pandemic: focused on the eosinophil count and ACE2
           expression

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2021 Sep 10. doi: 10.23822/EurAnnACI.1764-1489.233. Online ahead of print.ABSTRACTCurrently, the world is engaged with a coronavirus disease 2019 (COVID-19) caused by acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection. The Center for Disease Control and Prevention (CDC) has proposed moderate to severe asthma as a risk factor for COVID-19 susceptibility and severity. However, current evidences have not identified asthma in the top 10 comorbidities associated with COVID-19 fatalities. It raises the question that why patients with different type of asthma are not more vulnerable to SARS-CoV-2 infection like other respiratory infection. Increased number of eosinophils and elevated angiotensin-converting enzyme 2 (ACE2) expressions in asthma are suppos...
      PubDate: Fri, 10 Sep 2021 10:00:00 +010
      DOI: 10.23822/eurannaci.1764-1489.233. online ahead of print.abstractcurrently, the world is engaged with
       
  • Allergic rhinitis and COVID-19: friends or foes'

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2021 Sep 10. doi: 10.23822/EurAnnACI.1764-1489.234. Online ahead of print.ABSTRACTAllergic rhinitis (AR) is a common disease affecting up to 40% of the general population worldwide. In the Coronavirus 2019 (COVID-19) pandemic era, many observational studies analysing the effect of asthma and chronic obstructive pulmonary disease on the risk of developing COVID-19 were conducted, while data on AR are limited.In this paper, we review the risk of developing SARS-Cov-2 infection carried by AR patients, the outcomes of those with COVID-19 disease, and the COVID-19 influence on the allergic and nasal symptoms and the psychological status of AR patients, in both adult and paediatric populations.AR patients seem to be protected from COVID 19 infection. Even if data ab...
      PubDate: Fri, 10 Sep 2021 10:00:00 +010
      DOI: 10.23822/eurannaci.1764-1489.234. online ahead of print.abstractallergic rhinitis (ar) is a common d
       
  • Asthma and COVID-19 pandemic: focused on the eosinophil count and ACE2
           expression

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2021 Sep 10. doi: 10.23822/EurAnnACI.1764-1489.233. Online ahead of print.ABSTRACTCurrently, the world is engaged with a coronavirus disease 2019 (COVID-19) caused by acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection. The Center for Disease Control and Prevention (CDC) has proposed moderate to severe asthma as a risk factor for COVID-19 susceptibility and severity. However, current evidences have not identified asthma in the top 10 comorbidities associated with COVID-19 fatalities. It raises the question that why patients with different type of asthma are not more vulnerable to SARS-CoV-2 infection like other respiratory infection. Increased number of eosinophils and elevated angiotensin-converting enzyme 2 (ACE2) expressions in asthma are suppos...
      PubDate: Fri, 10 Sep 2021 10:00:00 +010
      DOI: 10.23822/eurannaci.1764-1489.233. online ahead of print.abstractcurrently, the world is engaged with
       
  • Allergic rhinitis and COVID-19: friends or foes'

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2021 Sep 10. doi: 10.23822/EurAnnACI.1764-1489.234. Online ahead of print.ABSTRACTAllergic rhinitis (AR) is a common disease affecting up to 40% of the general population worldwide. In the Coronavirus 2019 (COVID-19) pandemic era, many observational studies analysing the effect of asthma and chronic obstructive pulmonary disease on the risk of developing COVID-19 were conducted, while data on AR are limited.In this paper, we review the risk of developing SARS-Cov-2 infection carried by AR patients, the outcomes of those with COVID-19 disease, and the COVID-19 influence on the allergic and nasal symptoms and the psychological status of AR patients, in both adult and paediatric populations.AR patients seem to be protected from COVID 19 infection. Even if data ab...
      PubDate: Fri, 10 Sep 2021 10:00:00 +010
      DOI: 10.23822/eurannaci.1764-1489.234. online ahead of print.abstractallergic rhinitis (ar) is a common d
       
  • Asthma and COVID-19 pandemic: focused on the eosinophil count and ACE2
           expression

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2021 Sep 10. doi: 10.23822/EurAnnACI.1764-1489.233. Online ahead of print.ABSTRACTCurrently, the world is engaged with a coronavirus disease 2019 (COVID-19) caused by acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection. The Center for Disease Control and Prevention (CDC) has proposed moderate to severe asthma as a risk factor for COVID-19 susceptibility and severity. However, current evidences have not identified asthma in the top 10 comorbidities associated with COVID-19 fatalities. It raises the question that why patients with different type of asthma are not more vulnerable to SARS-CoV-2 infection like other respiratory infection. Increased number of eosinophils and elevated angiotensin-converting enzyme 2 (ACE2) expressions in asthma are suppos...
      PubDate: Fri, 10 Sep 2021 10:00:00 +010
      DOI: 10.23822/eurannaci.1764-1489.233. online ahead of print.abstractcurrently, the world is engaged with
       
  • Allergic rhinitis and COVID-19: friends or foes'

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Eur Ann Allergy Clin Immunol. 2021 Sep 10. doi: 10.23822/EurAnnACI.1764-1489.234. Online ahead of print.ABSTRACTAllergic rhinitis (AR) is a common disease affecting up to 40% of the general population worldwide. In the Coronavirus 2019 (COVID-19) pandemic era, many observational studies analysing the effect of asthma and chronic obstructive pulmonary disease on the risk of developing COVID-19 were conducted, while data on AR are limited.In this paper, we review the risk of developing SARS-Cov-2 infection carried by AR patients, the outcomes of those with COVID-19 disease, and the COVID-19 influence on the allergic and nasal symptoms and the psychological status of AR patients, in both adult and paediatric populations.AR patients seem to be protected from COVID 19 infection. Even if data ab...
      PubDate: Fri, 10 Sep 2021 10:00:00 +010
      DOI: 10.23822/eurannaci.1764-1489.234. online ahead of print.abstractallergic rhinitis (ar) is a common d
       
  • Rapid desensitization to acetylsalicylic acid in patients with ischemic
           heart disease: 10-year experience of a portuguese allergy department

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. In our cohort, RD to ASA in patients with ASA HS and IHD was very effective and safe.PMID:34313087
      DOI :10.23822/EurAnnACI.1764-1489.230 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Tue, 27 Jul 2021 10:00:00 +010
       
  • Severity and duration of allergic conjunctivitis: are they associated with
           severity and duration of allergic rhinitis and asthma'

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. The application of the new DECA classification for AC reveals a direct relationship between AC, rhinitis and asthma respect to severity and duration. These relationships suggest that AC should be considered an integral part of the "one airway, one disease" hypothesis.PMID:34313088
      DOI :10.23822/EurAnnACI.1764-1489.231 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Tue, 27 Jul 2021 10:00:00 +010
       
  • Rapid desensitization to acetylsalicylic acid in patients with ischemic
           heart disease: 10-year experience of a portuguese allergy department

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. In our cohort, RD to ASA in patients with ASA HS and IHD was very effective and safe.PMID:34313087
      DOI :10.23822/EurAnnACI.1764-1489.230 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Tue, 27 Jul 2021 10:00:00 +010
       
  • Severity and duration of allergic conjunctivitis: are they associated with
           severity and duration of allergic rhinitis and asthma'

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. The application of the new DECA classification for AC reveals a direct relationship between AC, rhinitis and asthma respect to severity and duration. These relationships suggest that AC should be considered an integral part of the "one airway, one disease" hypothesis.PMID:34313088
      DOI :10.23822/EurAnnACI.1764-1489.231 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Tue, 27 Jul 2021 10:00:00 +010
       
  • Rapid desensitization to acetylsalicylic acid in patients with ischemic
           heart disease: 10-year experience of a portuguese allergy department

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. In our cohort, RD to ASA in patients with ASA HS and IHD was very effective and safe.PMID:34313087
      DOI :10.23822/EurAnnACI.1764-1489.230 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Tue, 27 Jul 2021 10:00:00 +010
       
  • Severity and duration of allergic conjunctivitis: are they associated with
           severity and duration of allergic rhinitis and asthma'

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. The application of the new DECA classification for AC reveals a direct relationship between AC, rhinitis and asthma respect to severity and duration. These relationships suggest that AC should be considered an integral part of the "one airway, one disease" hypothesis.PMID:34313088
      DOI :10.23822/EurAnnACI.1764-1489.231 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Tue, 27 Jul 2021 10:00:00 +010
       
  • Rapid desensitization to acetylsalicylic acid in patients with ischemic
           heart disease: 10-year experience of a portuguese allergy department

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. In our cohort, RD to ASA in patients with ASA HS and IHD was very effective and safe.PMID:34313087
      DOI :10.23822/EurAnnACI.1764-1489.230 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Tue, 27 Jul 2021 10:00:00 +010
       
  • Severity and duration of allergic conjunctivitis: are they associated with
           severity and duration of allergic rhinitis and asthma'

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. The application of the new DECA classification for AC reveals a direct relationship between AC, rhinitis and asthma respect to severity and duration. These relationships suggest that AC should be considered an integral part of the "one airway, one disease" hypothesis.PMID:34313088
      DOI :10.23822/EurAnnACI.1764-1489.231 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Tue, 27 Jul 2021 10:00:00 +010
       
  • Rapid desensitization to acetylsalicylic acid in patients with ischemic
           heart disease: 10-year experience of a portuguese allergy department

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. In our cohort, RD to ASA in patients with ASA HS and IHD was very effective and safe.PMID:34313087
      DOI :10.23822/EurAnnACI.1764-1489.230 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Tue, 27 Jul 2021 10:00:00 +010
       
  • Severity and duration of allergic conjunctivitis: are they associated with
           severity and duration of allergic rhinitis and asthma'

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. The application of the new DECA classification for AC reveals a direct relationship between AC, rhinitis and asthma respect to severity and duration. These relationships suggest that AC should be considered an integral part of the "one airway, one disease" hypothesis.PMID:34313088
      DOI :10.23822/EurAnnACI.1764-1489.231 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Tue, 27 Jul 2021 10:00:00 +010
       
  • Rapid desensitization to acetylsalicylic acid in patients with ischemic
           heart disease: 10-year experience of a portuguese allergy department

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. In our cohort, RD to ASA in patients with ASA HS and IHD was very effective and safe.PMID:34313087
      DOI :10.23822/EurAnnACI.1764-1489.230 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Tue, 27 Jul 2021 10:00:00 +010
       
  • Severity and duration of allergic conjunctivitis: are they associated with
           severity and duration of allergic rhinitis and asthma'

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. The application of the new DECA classification for AC reveals a direct relationship between AC, rhinitis and asthma respect to severity and duration. These relationships suggest that AC should be considered an integral part of the "one airway, one disease" hypothesis.PMID:34313088
      DOI :10.23822/EurAnnACI.1764-1489.231 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Tue, 27 Jul 2021 10:00:00 +010
       
  • Rapid desensitization to acetylsalicylic acid in patients with ischemic
           heart disease: 10-year experience of a portuguese allergy department

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. In our cohort, RD to ASA in patients with ASA HS and IHD was very effective and safe.PMID:34313087
      DOI :10.23822/EurAnnACI.1764-1489.230 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Tue, 27 Jul 2021 10:00:00 +010
       
  • Severity and duration of allergic conjunctivitis: are they associated with
           severity and duration of allergic rhinitis and asthma'

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. The application of the new DECA classification for AC reveals a direct relationship between AC, rhinitis and asthma respect to severity and duration. These relationships suggest that AC should be considered an integral part of the "one airway, one disease" hypothesis.PMID:34313088
      DOI :10.23822/EurAnnACI.1764-1489.231 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Tue, 27 Jul 2021 10:00:00 +010
       
  • Rapid desensitization to acetylsalicylic acid in patients with ischemic
           heart disease: 10-year experience of a portuguese allergy department

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. In our cohort, RD to ASA in patients with ASA HS and IHD was very effective and safe.PMID:34313087
      DOI :10.23822/EurAnnACI.1764-1489.230 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Tue, 27 Jul 2021 10:00:00 +010
       
  • Severity and duration of allergic conjunctivitis: are they associated with
           severity and duration of allergic rhinitis and asthma'

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. The application of the new DECA classification for AC reveals a direct relationship between AC, rhinitis and asthma respect to severity and duration. These relationships suggest that AC should be considered an integral part of the "one airway, one disease" hypothesis.PMID:34313088
      DOI :10.23822/EurAnnACI.1764-1489.231 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Tue, 27 Jul 2021 10:00:00 +010
       
  • Rapid desensitization to acetylsalicylic acid in patients with ischemic
           heart disease: 10-year experience of a portuguese allergy department

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. In our cohort, RD to ASA in patients with ASA HS and IHD was very effective and safe.PMID:34313087
      DOI :10.23822/EurAnnACI.1764-1489.230 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Tue, 27 Jul 2021 10:00:00 +010
       
  • Severity and duration of allergic conjunctivitis: are they associated with
           severity and duration of allergic rhinitis and asthma'

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. The application of the new DECA classification for AC reveals a direct relationship between AC, rhinitis and asthma respect to severity and duration. These relationships suggest that AC should be considered an integral part of the "one airway, one disease" hypothesis.PMID:34313088
      DOI :10.23822/EurAnnACI.1764-1489.231 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Tue, 27 Jul 2021 10:00:00 +010
       
  • Rapid desensitization to acetylsalicylic acid in patients with ischemic
           heart disease: 10-year experience of a portuguese allergy department

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. In our cohort, RD to ASA in patients with ASA HS and IHD was very effective and safe.PMID:34313087
      DOI :10.23822/EurAnnACI.1764-1489.230 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Tue, 27 Jul 2021 10:00:00 +010
       
  • Severity and duration of allergic conjunctivitis: are they associated with
           severity and duration of allergic rhinitis and asthma'

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. The application of the new DECA classification for AC reveals a direct relationship between AC, rhinitis and asthma respect to severity and duration. These relationships suggest that AC should be considered an integral part of the "one airway, one disease" hypothesis.PMID:34313088
      DOI :10.23822/EurAnnACI.1764-1489.231 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Tue, 27 Jul 2021 10:00:00 +010
       
  • Rapid desensitization to acetylsalicylic acid in patients with ischemic
           heart disease: 10-year experience of a portuguese allergy department

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. In our cohort, RD to ASA in patients with ASA HS and IHD was very effective and safe.PMID:34313087
      DOI :10.23822/EurAnnACI.1764-1489.230 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Tue, 27 Jul 2021 10:00:00 +010
       
  • Severity and duration of allergic conjunctivitis: are they associated with
           severity and duration of allergic rhinitis and asthma'

    • Authors: European Annals of Allergy; Clinical Immunology
      Abstract: Conclusions. The application of the new DECA classification for AC reveals a direct relationship between AC, rhinitis and asthma respect to severity and duration. These relationships suggest that AC should be considered an integral part of the "one airway, one disease" hypothesis.PMID:34313088
      DOI :10.23822/EurAnnACI.1764-1489.231 (Source: European Annals of Allergy and Clinical Immunology)
      PubDate: Tue, 27 Jul 2021 10:00:00 +010
       
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 44.210.21.70
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-